U.S. Markets open in 8 hrs 32 mins

Applied Genetic Technologies Corporation (AGTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.7000+0.1400 (+3.93%)
At close: 4:00PM EDT

Applied Genetic Technologies Corporation

14193 NW 119th Terrace
Suite 10
Alachua, FL 32615
United States
386 462 2204
http://www.agtc.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees83

Key Executives

NameTitlePayExercisedYear Born
Ms. Susan B. WasherPres, CEO & Director795.26kN/A1961
Mr. Stephen W. PotterVP & Chief Bus. Officer486.77kN/A1956
Dr. Matthew FeinsodExec. VP of Global Strategy & Devel.549.67kN/A1971
Dr. Nicholas MuzyczkaCo-FounderN/AN/AN/A
Dr. Barry J. ByrneCo-FounderN/AN/AN/A
Dr. William W. HauswirthCo-Founder & Member of Ophthalmology Scientific Advisory BoardN/AN/AN/A
Dr. Richard Jude SamulskiCo-FounderN/AN/AN/A
Dr. Terence R. Flotte M.D.Co-FounderN/AN/AN/A
Mr. Gerald Anthony ReynoldsChief Accounting Officer, Principal Accounting Officer & TreasurerN/AN/AN/A
Ms. Janet C. Rae RACSr. VP of Global Regulatory & QualityN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.

Corporate Governance

Applied Genetic Technologies Corporation’s ISS Governance QualityScore as of July 1, 2021 is 6. The pillar scores are Audit: 9; Board: 1; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.